Verve Therapeutics

About Verve Therapeutics

Verve Therapeutics is dedicated to protecting the world from cardiovascular disease (CVD), the leading cause of death worldwide. Their mission is to revolutionize the treatment of CVD through the development of single-course gene editing medicines.

Products & Services

VERVE-102:A gene editing program targeting cardiovascular disease risk factors.

Heart-2 Trial:A clinical trial currently enrolling patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease to lower LDL-C by targeting the PCSK9 gene.

Specialties

Gene Editing Cardiovascular Disease Treatment In Vivo Gene Editing Programs Genetic Targets for CVD Risk Reduction

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 143800000 MR: - FA: approximately $143.8 million FAN: 143800000	D: 2023-12-01 FD: 2023-12-01	1 investors
2	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 35000000 MR: - FA: up to $35 million FAN: 35000000	D: 2023-11-28 FD: 2023-11-28	1 investors
3	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 148000000 MR: - FA: approximately $148.0 million FAN: 148000000	D: 2023-11-28 FD: 2023-11-28	1 investors

Public Offering and Private Placement Latest

2023-12-01

$143.8M

1 investor (Pro only)

Public Offering and Private Placement 2023-11-28

$35.0M

Public Offering and Private Placement 2023-11-28

$148.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News